The HER-2/neu oncogene in breast cancer: Prognostic factor, predictive factor, and target for therapy

Stem Cells

Volumn 16, Issue 6, 1998, Pages 413-428

  Ross, Jeffrey S ^a   Fletcher, Jonathan A ^b  

^a ALBANY MEDICAL COLLEGE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Breast neoplasms; HER 2 neu; Prognosis; Proto oncogene c erbB2; Therapy

Indexed keywords

DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; MONOCLONAL ANTIBODY;

ANTIGEN EXPRESSION; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER IMMUNOTHERAPY; HUMAN; ONCOGENE NEU; PREDICTION; PROGNOSIS; PROTO ONCOGENE; TREATMENT OUTCOME;

EID: 0031759864     PISSN: 10665099     EISSN: None     Source Type: Journal    
DOI: 10.1002/stem.160413     Document Type: Article

References (125)

1. Slamon DJ, Clark GM. Amplification of C-ERB-B2 and aggressive breast tumors? Science 1988;240:1795-1798.
2. De Potter CR. The neu oncogene: more than a prognostic indicator? Hum Pathol 1994;25:1264-1268.
3. Lupu R, Cardillo M, Harris L et al. Interaction between ERB-receptors and heregulin in breast cancer tumor progression and drug resistance. Sem Cancer Biol 1995;6:135-145.
4. Slamon DJ, Clark GM, Wong SG et al. Human breast cancer: correlation of relapse and survival with amplification of the Her-2/neu oncogene. Science 1987;235:177-182.
5. Berger MS, Locher GW, Saurer S et al. Correlation of c-erb B2 gene amplification and protein expression in human breast carcinoma with nodal status and nuclear grading. Cancer Res 1988;48:1238-1243.
6. van de Vivjer MJ, Peterse JL, Mooi WJ et al. Neu-protein over-expression in breast cancer. N Engl J Med 1988;319:1239-1245.
7. Heintz NH, Leslie KO, Rogers LA et al. Amplification of the c-erb B-2 oncogene in prognosis of breast adenocarcinoma. Arch Pathol Lab Med 1990;114:160-163.
8. Tsuda H, Hirohashi S, Shimosato Y et al. Correlation between histologic grade of malignancy and copy number of c-erbB-2 gene in breast carcinoma. A retrospective analysis of 176 cases. Cancer 1990; 65:1794-1800.
9. Borg A, Tandon AK, Sigurdsson H et al. HER-2/new amplification predicts poor survival in node-positive breast cancer. Cancer Res 1990;50:4332-4337.
10. Paik S, Hazan R, Fisher ER et al. Pathologic findings from the nations' surgical adjuvant breast and bowel project: prognostic significance of erb B2 protein overexpression in primary breast cancer. J Clin Oncol 1990;8:103-112.
11. Battifora H, Gaffey M, Esteban J et al. Immunohistochemical assay of neu/c-erb B-2 oncogene product in paraffin-embedded tissues in early breast cancer: Retrospective follow-up study of 245 stage I and II cases. Modern Pathol 1991;4:466-474.
12. Kallioniemi OP, Holli K, Visakorpi T et al. Association of C-erb B2 protein over-expression with high rate of cell proliferation, increased risk of visceral metastasis and poor long-term survival in breast cancer. Int J Cancer 1991;49:650-655.
13. Clark GM, McGuire WL. Follow-up study of HER-2/nen amplification in primary breast cancer. Cancer Res 1991;51:944-948.
14. Lovekin C, Ellis IO, Locker A et al. C-erb B2 oncoprotein expression in primary and advanced breast cancer. Br J Cancer 1991;63:439-443.
15. McCann AH, DeDervan TA, O'Regan M et al. Prognostic significance of C-erb B2 and estrogen receptor status in human breast cancer. Cancer Res 1991;51:3296-3303.
16. Dykens R, Corbett IP, Henry J et al. Long term survival in breast cancer related to overexpression of the C-erb B2 oncoprotein: an immunohistochemical study using monoclonal antibody NCL-CB11. J Pathol 1991;163:105-110.
17. Rilke F, Colnaghi MI, Cascinelli N et al. Prognostic significance of UER-2/neu expression in breast cancer and its relationship to other prognostic factors. Int J Cancer 1991;49:44-49.
18. Winstanley J, Cooke T, Murray GD et al. The long term prognostic significance of C-erb B2 in primary breast cancer. Br J Cancer 1991;63:447-450.
19. O'Reilly SM, Barnes DM, Camplejohn RS et al. The relationship between C-erb B2 expression, and s-phase fraction in prognosis in breast cancer. Br J Cancer 1991;63:444-446.
20. Paterson MC, Dietrich KD, Danyluk J et al. Correlation between C-erb B2 amplification and risk of recurrent disease in node-negative breast cancer. Cancer Res 1991;51:556-567.
21. Toikkanen S, Helin H, Isola J et al. Prognostic significance of Her-2 oncoprotein expression in breast cancer: a 30-year follow up. J Clin Oncol 1992;10:1044-1048.
22. Molina R, Ciocca DR, Candon AK et al. Expression of HER-2/neu oncoprotein in breast cancer: a comparison of immunohistochemical and western blot techniques. Anticancer Res 1992;12:1965-1991.
23. Noguchi M, Koyasaki M, Ohta N et al. c-erb B-2 oncoprotein expression versus internal mammary lymph node metastases as additional prognostic factors in patients with axillary lymph node-positive breast cancer. Cancer 1992;69:2953-2960.
24. Allred DC, Clark GM, Tandon AK et al. HER-2/neu node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in-situ carcinoma. J Clin Oncol 1992;10:599-605.
25. Babiak J, Hugh J, Poppeme S. Significance of c-erb B-2 amplification in DNA aneuploidy. Analysis in 78 patients with node-negative breast cancer. Cancer 1992;70:770-776.
26. Tiwari RK, Borgen PI, Wong GY et al. HER-2/neu amplification and overexpression in primary human breast cancer is associated with early metastasis. Anticancer Res 1992;12:419-426.
27. Gusterson BA, Gelber RD, Goldhirsch A et al. Prognostic importance of C-erb B2 expression in breast cancer. J Clin Oncol 1992;10:1049-1056.
28. Bianchi S, Paglierani M, Zampi G et al. Prognostic significance of C-erb B2 expression in node negative breast cancer. Br J Cancer 1993;67:625-629.
29. Press MF, Pike MC, Chazin VR et al. Her-2/neu expression in node-negative breast cancer: direct tissue quantification by computerized image analysis and association of overexpression with increased risk of recurrent disease. Cancer Res 1993;53:4960-4970.
30. Seshadri R, Firgaira FA, Horsfall DJ et al. Clinical significance of Her-2/neu oncogene amplification in primary breast cancer. J Clin Oncol 1993;11:1936-1942.
31. Descotes F, Pavy J-J, Adessi GL. Human breast cancer: correlation study between Her-2/neu amplification and prognostic factors in an unselected population. Anticancer Res 1993;13:119-124.
32. Giai M, Roagna R, Ponzone R et al. Prognostic and predictive relevance of C-erb B2 and ras expression in node-positive and negative breast cancer. Anticancer Res 1994;14:1441-1450.
33. Muss HB, Thor AD, Berry DA et al. Cerb-B2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 1994;330:1260-1266.
34. Tetu B, Brisson J. Prognostic significance of Her-2/neu oncogene expression in node-positive breast cancer. The influence of the pattern of immunostaining and adjuvant therapy. Cancer 1994;73:2359-2365.
35. Hartmann LC, Ingle JN, Wold LE et al. Prognostic value of CerbB2 overexpression in axillary lymph node-positive breast cancer. Results from a randomized adjuvant treatment protocol. Cancer 1994;74:2956-2963.
36. Jacquemier J, Penault-Llorca P, Viens P et al. Breast cancer response to adjuvant chemotherapy in correlation with erb B2 and p53 expression. Anticancer Res 1994;14:2773-2778.
37. Marks JR, Humphrey PA, Wu K at al. Overexpression of p53 and Her-2/neu proteins as prognostic markers in early stage breast cancer. Ann Surg 1994;219:332-341.
38. Rosen PP, Lesser ML, Arroyo CD et al. Immunohistochemical detection of Her-2/neu expression in patients with axillary lymph node-negative breast carcinoma. A study of epidemiologic risk factors, histologic features and prognosis. Cancer 1995;75:1320-1326.
39. Quenel N, Wafflart J, Bonichon F et al. The prognostic value of c-erbB2 in primary breast carcinomas: a study on 942 cases. Breast Cancer Res Treat 1995;35:283-291.
40. Sundblad AS, Pellicer EM, Ricci L. Carcinoembryonic expression in stages I and II breast cancer; its relationship with clinicopathologic factors. Hum Pathol 1996;27:297-300.
41. O'Malley FP, Saad Z, Kerkvliet N et al. The predictive power of semiquantitative immunohistochemical assessment of p53 and C-erbB2 in lymph node-negative breast cancer. Hum Pathol 1996;27:955-963.
42. Hieken TJ, Mehta RR, Shilkaitis A et al. Her-2/neu and p53 expression in breast cancer: valid prognostic markers when assessed by direct immunoassay, but not by immunochemistry. Proc Annu Meet Am Soc Clin Oncol 1996;15:113a.
43. Xing W-R, Gilchrist KW, Harris CP et al. FISH detection of HER-2/neu oncogene amplification in early onset breast cancer. Breast Cancer Res Treat 1996;39:203-212.
44. Dittadi R, Brazzale A, Pappagallo G et al. ErbB2 assay in breast cancer: possibly improved clinical information using a quantitative method. Anticancer Res 1997;17:1245-1247.
45. Fernandez-Acenero MJ, Farina Gonzalez J, Arangoncillo Ballesteros P. Immunohistochemical expression of p53 and c-erbB-2 in breast carcinoma: relation with epidemiologic factors, histologic features and prognosis. Gen Diagn Pathol 1997;142:289-296.
46. Eissa S, Khalifa A, el-Gharib A et al. Multivariate analysis of DNA ploidy, p53, c-erbB-2 proteins, EGFR, and steroid hormone receptors for short-term prognosis in breast cancer. Anticancer Res 1997;17:3091-3097.
47. Charpin C, Garcia S, Bouvier C et al. c-erbB-2 oncoprotein detected by automated quantitative immunocytochemistry in breast carcinomas correlates with patients' overall and disease-free survival. Br J Cancer 1997;75:1667-1673.
48. Press MJ, Bernstein L, Thomas PA et al. Her-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. J Clin Oncol 1997;15:2894-2904.
49. Ross JS, Muraca PJ, Jaffe D et al. Multivariate analysis of prognostic factors in lymph node negative breast cancer. Mod Pathol 1998;11:26a.
50. cdc2 cyclin dependent kinase and MIB1 overexpression, and HER-2/neu gene amplification detected by fluorescence in-situ hybridization in breast cancer. Mod Pathol 1998;11:18A.
51. Page DL. Prognosis and breast cancer. Recognition of lethal and favorable prognostic types. Am J Surg Pathol 1991;15:334-349.
52. Porter-Jordan K, Lippman ME. Overview of the biologic markers in breast cancer. Hematol Oncol Clin North Am 1994;8:73-100.
53. McGuire WL, Tandon AK, Allred DC et al. How to use prognostic factors in axillary node-negative breast cancer patients. J Natl Cancer Inst 1990;82:1006-1015.
54. Pauletti G, Godolphin W, Press MF et al. Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. Oncogene 1996;13:63-72.
55. Sauter G, Feichter G, Torhorst J et al. Fluorescence in-situ hybridization for detecting ERBB-2 amplification in breast tumor fine needle aspiration biopsies. Acta Cytol 1996;40:164-173.
56. Allred DC, Harvey JM, Berardo M et al. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 1998;11:155-168.
57. Jacobs TW, Prioleau JE, Stillman IE et al. Loss of tumor marker-immunostaining intensity on stored paraffin slides of breast cancer. J Natl Cancer Inst 1996;88:1054-1059.
58. Penault-Llorca F, Adelaide J, Houvenaeghel G et al. Optimization of immunohistochemical detection of ERBB2 in human breast cancer: impact of fixation. J Pathol 1994;173:65-75.
59. Busmanis I, Feleppa F, Jones A et al. Analysis of C-erb B2 expression using a panel of six commercially available antibodies. Pathol 1994;26:261-267.
60. Press MF, Hung G, Godolphin W et al. Sensitivity of Her-2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression. Cancer Res 1994;54:2771-2777.
61. vanDiest PJ, vanDam P, Henzen-Logmans SC et al. A scoring system for immunohistochemical staining: consensus report of the Task Force for Basic Research of the EORTC-GCGC. J Clin Pathol 1997;50:801-804.
62. Lodato RF, Maguire HC, Greene MI et al. Immunohistochemical evaluation of cerb B2 oncogene expression in ductal carcinoma in situ and atypical ductal hyperplasia of the breast. Mod Pathol 1990;3:449-454.
63. Allred DC, Clark GM, Molina R et al. Overexpression of Her-2/neu and its relationship with other prognostic factors changed during progression of in-situ to invasive breast cancer. Hum Pathol 1992;23:974-979.
64. Zafrani B, Leroyer A, Fourquet A et al. Mammographically-detected ductal in-situ carcinoma of the breast analyzed with a new classification. Sem Diagn Pathol 1994;11:208-214.
65. Brower FT, Ahmed S, Tartter P et al. Prognostic variables in invasive breast cancer: Contribution of comedo versus non-comedo in-situ component. Ann Surg Oncol 1995;2:440-444.
66. Leal CB, Schmitt FC, Bento NJ et al. Ductal carcinoma in-situ of the breast. Histologic categorization and its relationship to ploidy and immunohistochemical expression of hormone receptors, p53 and C erb B-2 protein. Cancer 1995;75:2123-2131.
67. Bobrow WLG, Happerfield LC, Gregory WM et al. Ductal carcinoma in-situ: assessment of necrosis in nuclear morphology and their association with biological markers. J Pathol 1995;176:333-341.
68. DePotter CR, Schelhout AM, Verbeeck P et al. neu overexpression correlates with extent of disease in large cell ductal in situ carcinoma of the breast. Hum Pathol 1995;26:601-606.
69. Inaji H, Koyama H, Motomura K et al. Differential distribution of erb B2 and pS2 proteins in ductal carcinoma in-situ of the breast. Breast Cancer Res Treat 1996;37:89-92.
70. Albonico G, Querzoli P, Ferretti S et al. Biophenotypes of breast carcinoma in-situ defined by image analysis of biological parameters. Pathol Res Pract 1996;192:117-123.
71. Bose S, Lesser ML, Norton L et al. Immunophenotype of intraductal carcinoma. Arch Pathol Lab Med 1996;120:81-85.
72. Moreno A, Lloveras B, Figueras A et al. Ductal carcinoma in-situ of the breast: Correlation between histologic classification and biologic markers. Mod Pathol 1997;10:1088-1092.
73. Mack L, Kerkzelit N, Doig G et al. Relationship of a new histological categorization of ductal carcinoma in-situ of the breast with size and the immunohistochemical expression of p53, C-erb B2, bcl2 and ki-67. Hum Pathol 1997;28:974-979.
74. Porter PL, Garcia R, Moe R et al. cerb B2 oncogene protein in in-situ and invasive lobular breast neoplasia. Cancer 1991;68:331-334.
75. Wolber RA, DuPuis BA, Wick MR. Expression of cerb B2 oncoprotein in mammary and extramammary Paget's disease. Am J Clin Pathol 1991;96:243-247.
76. Lilleng R, Hagmar BM, Nesland JM. cerb B2 protein and neuroendocrine expression in intraductal carcinomas of the breast. Mod Pathol 1992;5:41-47.
77. Yeh I-T, Keykhah S, Selig AM et al. Expression of erb B2 gene in the benign and proliferative breast tissue. Surg Pathol 1993;5:109-120.
78. Hanna W, Kahn HJ, Andrulis I et al. Distribution and patterns of staining of neu oncogene product in benign and malignant breast diseases. Mod Pathol 1990;3:455-461.
79. Odagiri E, Kanda N, Jibiki K et al. Reduction of telomeric-linked cerb B2 gene amplification in human breast cancer, fibroadenoma, and gynecomastia. Relationship to histologic grade and clinical parameters. Cancer 1994;73:2978-2984.
80. Gattuso P, Reddy VB, Green LK et al. Prognostic factors for carcinoma of the male breast. Int J Surg Pathol 1995;2:199-206.
81. Joshi MG, Lee AK, Loda M et al. Male breast carcinoma: an evaluation of prognostic factors contributing to a poorer outcome. Cancer 1996;77:490-498.
82. Willsher PC, Leach IH, Ellis IO et al. Male breast cancer: pathological and immunohistochemical features. Anticancer Res 1997;17:2335-2338.
83. Bines J, GOSS B, Hussong J et al. C-erb and p53 overexpression as predictors of survival in patients with male breast cancer. Proc Ann Assoc Clin Oncol 1997;16:558a.
84. Bruce DM, Heyes SD, Payne S et al. Male breast cancer: clinico-pathological features, immunocytochemical characteristics and prognosis. Eur J Surg Oncol 1996;22:42-46.
85. Dawson PJ, Paine TM, Wolman SR. Immunocytochemical characterization of male breast cancer. Mod Pathol 1992;5:621-625.
86. Wright C, Nicholson S, Angus B et al. Relationship between C-ERBB 2 protein product expression and response to endocrine therapy in advanced breast cancer. Br J Cancer 1992;65:118-121.
87. Leitzel K, Teramoto Y, Konrad K et al. Elevated serum C-erb B2 antigen levels and decreased response to hormone therapy of breast cancer. J Clin Oncol 1995;13:1129-1135.
88. Berns EM, Foekens JA, vanStaveren IL et al. Oncogene amplification and prognosis in breast cancer: relationship with systemic treatment. Gene 1995;159:11-18.
89. Stahl O, Sullivan S, Wingren S et al. C-erbB2 expression and benefit from adjuvant chemotherapy and radiotherapy of breast cancer. Eur J Cancer 1995;31:2185a-2190a.
90. Archer SG, Eliopoulis SA, Spandidos D et al. Expression of ras p21, p53 and C-erb B2 in advanced breast cancer and response to line hormonal therapy. Br J Cancer 1995;72:1259-1266.
91. Yu D, Liu B, Tan M et al. Overexpression of cerbB2/neu in breast cancer cells confers increased resistance to Taxol via mdr-1-independent mechanisms. Oncogene 1996;13:1359-1365.
92. Carlomagno C, Perrone F, Gallo C et al. CerbB2 overexpression decreases the benefit of adjuvant Tamoxifen in early-stage breast cancer without ancillary lymph node metastases. J Clin Oncol 1996;14:2702-2708.
93. Haffty BG, Brown F, Carter D et al. Evaluation of HER-2/neu oncoprotein expression as a prognostic indicator of local recurrence in conservatively treated breast cancer: a case-control study. Int J Rad Oncol Biol Phys 1996;35:751-757.
94. Revillion F, Hebbar M, Boneterre J et al. Plasma CerbB2 concentrations in relations to chemotherapy in breast cancer patients. Eur J Cancer 1996;32:231a-234a.
95. Baselga J, Seidman AD, Rosen PP et al. HER-2 overexpression and paclitaxel sensitivity in breast cancer: therapeutic implications. Oncology 1997;11:43-48.
96. Pegram MD, Finn RS, Arzoo K et al. The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells. Oncogene 1997;15:537-547.
97. Newby JC, Johnston SRD, Smith IE et al. Expression of epidermal growth factor receptor and C-erb B2 during the development of tamoxifen resistance in human breast cancer. Clin Cancer Res 1997;3:1643-1651.
98. Burke HB, Hoang A, Iglehart JD et al. Predicting response to adjuvant and radiation therapy in patients with early stage breast carcinoma. Cancer 1998;82:874-877.
99. Yamauchi H, O'Neill A, Gelman R et al. Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the HER-2/c-neu protein. J Clin Oncol 1997;15:2518-2525.
100. Elledge RM, Green S, Ciocca D et al. HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer a Southwest Oncology Group study. Clin Cancer Res 1998;4:7-12.
101. Bianco AR, De Laurentiis M, Carlomagno C et al. 20 year update of the Naples Gun trial of adjuvant breast cancer therapy: eveidence of interaction between c-erb-B2 expression and tamoxifen efficacy. Proc Am Soc Clin Oncol 1998;17:97a.
102. Ravdin PM, Green S, Albain V et al. Initial report of the SWOG biological correlative study of c-ERBB2 expression as a predictor of outcome in a trial comparing adjuvant CAF with Tamoxifen alone. Proc Am Soc Clin Oncol 1998;17:97a.
103. Isola JJ, Holli K, Oksa H et al. Elevated erb B-2 oncoprotein levels in preoperative and follow-up serum samples defined in aggressive course in patients with breast cancer. Cancer 1994;73:652-658.
104. Kandl H, Seymour L, Bezwoda WR. Soluble c-erb B-2 fragments in serum correlates with disease stage and predicts more shortened survival in patients with early-stage and advanced breast cancer. Br J Cancer 1994;70:739, 742.
105. Wu JT, Astill ME, Gagon SD et al. Measurement of C-erb B 2 proteins in sera from patients with carcinomas and in breast tumor tissue cytosols: correlation with serum tumor markers and membrane-bound oncoproteins. J Clin Lab Anal 1995;9:151-165.
106. Andersen TI, Paus E, Nesland JM et al. Detection of C-erb B2 related proteins in sera from breast cancer patients. Relationship to ERBB2 gene amplification and Cerb B2 protein overexpression in tumour. Acta Oncol 1995;34:499-504.
107. Volas GH, Leitzel K, Teramoto Y et al. Serial serum C-erbB-2 levels in patients with breast carcinoma. Cancer 1996;78:267-272.
108. Molina R, Jo J, Vanon G et al. Utility of cerbB2 in tissue and in serum in the early diagnosis of recurrence in breast cancer patients: comparison with carcinoembryonic antigen and CA15.3. Br J Cancer 1996;74:1126-1131.
109. Willsher PC, Beaver J, Pinder S et al. Prognostic significance of serum CerbB2 protein in breast cancer patients. Breast Cancer Res Treat 1996;40:251-255.
110. Fehm T, Maimonis P, Wetz S et al. Influence of circulating C-erbB-2 serum protein on response to adjuvant chemotherapy in node-positive breast cancer patients. Breast Cancer Res Treat 1997;43:87-95.
111. Mansour OA, Zekri AR, Harvey J et al. Tissue in serum CerbB2 and tissue EGFR in breast carcinoma: three years follow-up. Ami Cancer Res 1997;17:3101-3106.
112. Shepard HM, Lewis GD, Sarup JC et al. Monoclonal antibody therapy of human cancer: taking the Her-2 proto-oncogene to the clinic. J Clin Immunol 1991;11:117-127.
113. Zhang L, Chang C, Bacus SS et al. Suppressed transformation and induced differentiation of Her-2/neu - overexpressing breast cancer cells by emodin. Cancer Res 1995;55:3890-3896.
114. Valone FH, Kaufman PA, Guyre PM et al. Phase Ia/Ib trial of bispecific antibody MDX-210 in patients with advanced breast or ovarian cancer that overexpresses the proto-oncogene HER-2/neu. J Clin Oncol 1995;13:2281-2292.
115. Jinno H, Ueda M, Enomoto K et al. Effectiveness of an Adriamycin immunoconjugate that recognizes the CerbB2 product on breast cancer cell lines. Surg Today 1996;26:501-507.
116. Baselga J, Tripathy D, Mendelsohn J et al. Phase II study of weekly intravenous recombinant humanized anti p 185 Her-2 monoclonal antibody in patients with Her-2/neu overexpressing metastatic breast cancer. J Clin Oncol 1996;14:737-744.
117. Liu X, Pogo BG. Inhibition of erbB2 positive breast cancer cell growth by erbB2 antisense oligonucleotides. Antisense Nucleic Acid Drug Devel 1996;6:9-16.
118. Wright M, Grim J, Deshane J et al. An intracellular anti-erbB-2 single-chain antibody is specifically cytotoxic to human breast carcinoma cells overexpressing erbB-2. Gene Ther 1997;4:317-322.
119. Heijnen IA, Buhring HJ, Deo YN et al. The clinical studies with Fc (Gamma) R by specific antibodies and granulocyte colony-stimulating factor-primed neutrophils as effector cells against HER-2/neu overexpression in breast cancer. Cancer Res 1997;57:696-701.
120. Witters LM, Kumar R, Chinchilli ZM et al. Enhanced anti-proliferative activity of the combination of tamoxifen plus HER-2-neu antibody. Breast Cancer Res Treat 1997;42:1-5.
121. Cobleigh MA, Vogel CL, Tripathy NJ et al. Efficacy and safety of Herceptin® (humanized anti-human HER-2 antibody) as a single agent in 222 women with HER2 overexpression who relapsed following chemotherapy for metastatic breast cancer. Proc Am Soc Clin Oncol 1998;17:97a.
122. Slamon D, Leyland-Jones B, Shak S et al. Addition of Herceptin® (humanized anti HER2 antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer markedly increases anticancer activity: a randomized, multinational controlled phase III trial. Proc Am Soc Clin Oncol 1998;17:98a.
123. Brossart P, Stuhler J, Flad P et al. Her-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes. Cancer Res 1998;58:732-736.
124. Disis ML, Grabstein KH, Cheaver MA, HER-2/neu peptide vaccines elicit T cell immunity to the HER-2/neu protein in patients with breast and ovarian cancer. Proc Am Soc Clin Oncol 1998;17:97a.
125. Allan SM, Dean CJ, Eccles S et al. Clinicoradioimmunolocalization with a rat monoclonal antibody directed against C-erb B2. Cell Biophys 1994;24:93-98.